Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.

Fiche publication

Date publication

novembre 2011


Membres identifiés du Cancéropôle Est :
Pr CHENARD Marie-Pierre, Dr DEBIEUVRE Didier, Dr LIMACHER Jean-Marc, Pr WESTEEL Virginie

Tous les auteurs :
Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard MP, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy JY, Limacher JM


BACKGROUND: Chemotherapy is the standard of care for advanced stages of non-small-cell lung cancer (NSCLC). TG4010 is a targeted immunotherapy based on a poxvirus (modified vaccinia virus Ankara) that codes for MUC1 tumour-associated antigen and interleukin 2. This study assessed TG4010 in combination with first-line chemotherapy in advanced NSCLC. METHODS: 148 patients with advanced (stage IIIB [wet] or IV) NSCLC expressing MUC1 by immunohistochemistry, and with performance status 0 or 1, were enrolled in parallel groups in this open-label, phase 2B study. 74 patients were allocated to the combination therapy group, and received TG4010 (10(8) plaque forming units) plus cisplatin (75 mg/m(2) on day 1) and gemcitabine (1250 mg/m(2) on days 1 and 8) repeated every 3 weeks for up to six cycles. 74 patients allocated to the control group received the same chemotherapy alone. Patients were allocated using a dynamic minimisation procedure stratified by centre, performance status, and disease stage. The primary endpoint was 6-month progression-free survival (PFS), with a target rate of 40% or higher in the experimental group. Analyses were done on an intention-to-treat basis. This study is completed and is registered with, number NCT00415818. FINDINGS: 6-month PFS was 43.2% (32 of 74; 95% CI 33.4-53.5) in the TG4010 plus chemotherapy group, and 35.1% (26 of 74; 25.9-45.3) in the chemotherapy alone group. Fever, abdominal pain, and injection-site pain of any grade according to National Cancer Institute Common Toxicity Criteria were more common in the TG4010 group than in the chemotherapy alone group: 17 of 73 patients (23.3%) versus six of 72 (8.3%), 12 (16.4%) versus two (2.8%), and four (5.5%) versus zero (0%), respectively. The most common grade 3-4 adverse events were neutropenia (33 [45.2%] of patients in the TG4010 plus chemotherapy group vs 31 [43.1%] in the chemotherapy alone group) and fatigue (18 [24.7%] vs 13 [18.1%]); the only grade 3-4 events that differed significantly between groups were anorexia (three [4.1%] vs 10 [13.9%]) and pleural effusion (none vs four [5.6%]). 38 of 73 patients (52.1%) in the TG4010 plus chemotherapy group and 34 of 72 (47.2%) in the chemotherapy alone group had at least one serious adverse event. INTERPRETATION: This phase 2B study suggests that TG4010 enhances the effect of chemotherapy in advanced NSCLC. A confirmatory phase 2B-3 trial has been initiated. FUNDING: Transgene SA, Advanced Diagnostics for New Therapeutic Approaches (ADNA)/OSEO.


Lancet Oncol. 2011 Nov;12(12):1125-33